TECH logo

Bio-Techne Corporation Stock Price

NasdaqGS:TECH Community·US$9.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 17 Fair Values set on narratives written by author

TECH Share Price Performance

US$58.66
-14.32 (-19.62%)
21.8% undervalued intrinsic discount
US$75.00
Fair Value
US$58.66
-14.32 (-19.62%)
26.7% undervalued intrinsic discount
US$80.00
Fair Value
Price US$58.66
AnalystHighTarget US$80.00
AnalystConsensusTarget US$66.23
AnalystLowTarget US$54.08

TECH Community Narratives

AnalystHighTarget·
Fair Value US$75 19.3% undervalued intrinsic discount

Rising Healthcare Spending And Aging Population Will Expand Biotech Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$66.23 8.6% undervalued intrinsic discount

Chronic Disease Trends And Precision Medicine Will Shape Demand

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AnalystLowTarget·
Fair Value US$53 14.3% overvalued intrinsic discount

US Funding Uncertainty Will Squeeze Life Sciences Yet Spark Resilience

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative

Recent TECH News & Updates

Bio-Techne: Coveted Life Sciences Asset On Sale Due To Academic Pressures

Aug 05

Investors Still Waiting For A Pull Back In Bio-Techne Corporation (NASDAQ:TECH)

Jul 28
Investors Still Waiting For A Pull Back In Bio-Techne Corporation (NASDAQ:TECH)

What Does Bio-Techne Corporation's (NASDAQ:TECH) Share Price Indicate?

May 29
What Does Bio-Techne Corporation's (NASDAQ:TECH) Share Price Indicate?

Bio-Techne Corporation Key Details

US$1.2b

Revenue

US$408.5m

Cost of Revenue

US$811.1m

Gross Profit

US$737.8m

Other Expenses

US$73.4m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
0.47
Gross Margin
66.50%
Net Profit Margin
6.02%
Debt/Equity Ratio
18.0%

Bio-Techne Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with moderate growth potential.

2 Risks
2 Rewards

About TECH

Founded
1976
Employees
3100
CEO
Kim Kelderman
WebsiteView website
www.bio-techne.com

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: 0.3%
  • 3 Months: 8.5%
  • 1 Year: 17.3%
  • Year to Date: 15.0%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. As for the longer term, the market has risen 17% in the past 12 months. Earnings are forecast to grow by 15% annually. Market details ›